JPRN-UMIN000005761已完成未知
The Study for Efficacy and Safety of Adalimumab for Crohn's Disease with Loss of Response to Infliximab - The Efficacy of Adalimumab
Kenji Watanabe0 个研究点目标入组 50 人开始时间: 2011年6月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)The patient of contraindication for adalimumab as following a.serious infections b.active tuberculosis c.hypersensitivity d.neurologic reactions (peripheral demyelinating disease) e.congestive heart failure 2)The case which is hard to get the patient's consent 3)The patient who was judged for unsuitable by responsibility doctor
研究者
相似试验
已完成
2 期
Evaluating the effects of Adalimumab in patients with acute respiratory distress syndrome caused by COVID-19IRCT20151227025726N23Shahid Beheshti University of Medical Sciences60
已完成
2 期
Adalimumab effectiveness in COVID-19COVID-19.C0VID-19U07.1IRCT20150303021315N22Tehran University of Medical Sciences40
进行中（未招募）
不适用
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYActive Ankylosing SpondylitisEUCTR2005-004826-21-BEAbbott GmbH & Co. KG1,200
进行中（未招募）
1 期
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYActive Ankylosing SpondylitisEUCTR2005-004826-21-DKAbbott GmbH & Co. KG1,200
进行中（未招募）
不适用
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYEUCTR2005-004826-21-GRAbbott GmbH & Co. KG1,200